Biology of Blood and Marrow Transplantation
Volume 14, Issue 4 , Pages 409-417 , April 2008

ABO Incompatibility is Associated with Increased Non-Relapse and GVHD Related Mortality in Patients with Malignancies Treated with a Reduced Intensity Regimen: A Single Center Experience of 221 Patients

Received 8 March 2006 ,Accepted 5 January 2008.

References 

  1. Landsteiner K. Individual differences in human blood. Science. 1931;73:403–409
  2. Klumpp TR. Immunohematological complications of bone marrow transplantation. Bone Marrow Transplant. 1991;8:159–170
  3. Buckner CD, Clift RA, Sanders JE, et al. ABO incompatible marrow transplants. Transplantation. 1978;26:233–238
  4. Bensinger WI, Buckner CD, Thomas RD, et al. ABO incompatible marrow transplants. Transplantation. 1982;33:427–429
  5. Mielcarek M, Leisenring W, Torok-Storb B, et al. Graft versus host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma effect. Blood. 2000;96:1150–1156
  6. Benjamin RJ, McGurk S, Ralston MS, et al. ABO-incompatibility as an adverse risk factor for survival after allogeneic marrow transplantation. Transfusion. 1999;39:179–187
  7. Stussi G, Seebach L, Muntwyler J, et al. Graft versus host disease and survival after ABO incompatible allogeneic bone marrow transplantation: a single center experience. Br J Haematol. 2001;113:251–253
  8. Seebach JD, Stussi G, Passweg JR, et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant. 2005;11:1006–1013
  9. Lapierre V, Oubouzar N, Auperin A, et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood. 2001;97:2580–2586
  10. Toren A, Dacosta Y, Manny N, et al. Passenger B-lymphocyte-induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation. Blood. 1996;87:843–844
  11. Laurencet FM, Samii K, Bressoud A, et al. Massive delayed hemolysis following peripheral blood stem cell transplantation with minor ABO incompatibility. Hematol Cell Ther. 1997;39:159–162
  12. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756–763
  13. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15;89(12):4531–4536
  14. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001 Jun 1;97(11):3390–3400
  15. Canals C, Muniz-Diaz E, Martinez C, et al. Impact of ABO-incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Transfusion. 2004;44:1603–1611
  16. Worel N, Kalhs P, Keil F, et al. ABO-mismatch increases transplant related morbidity and mortality in patients given non-myeloablative allogeneic HPC transplantation. Transfusion. 2003;43:1153–1161
  17. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825–828
  18. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981 Feb;57(2):267–276
  19. Junghanss C, Marr KA, Carler RA, et al. Incidence and outcome of bacterial and fungal infections following non-myeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002;8:512–520
  20. Kim JG, Sohn SK, Kim DH, et al. Impact of ABO-incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2005;35:489–495
  21. Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98:1687–1694
  22. Sniecinski IJ, Oien L, Petz LD, et al. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation. 1988;45:530–533
  23. Gajewski JL, Petz LD, Calhoun L, et al. Hemolysis of transfusion group O red blood cells in minor ABO-incompatible unrelated donor bone marrow transplants in patients receiving cyclosporine without post-transplant methotrexate. Blood. 1992;79:3076–3085
  24. Peggs KS, Morris EC, Kottaridis PD, et al. Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen. Blood. 2002;99:4642–4643
  25. Badros A, Tricot G, Toor A, et al. ABO-mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002;42:205–209
  26. Tomonari A, Takahashi S, Ooi J, et al. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan. Bone Marrow Transplant. 2007 Sep;40(6):523–528
  27. Rowley SD, Liang PS, Ulz L. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell component. Bone Marrow Transplant. 2000;26:749–757
  28. Blacklock HA, Katz F, Michalevicz R, et al. A and B blood group antigen expression on mixed colony cells and erythroid precursors: relevance for human allogeneic bone marrow transplantation. Br J Haematol. 1984;58:267–276
  29. Kanda Y, Tanosaki R, Nakai K, et al. Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic hematopoietic stem cell transplantation from an ABO-incompatible donor. Br J Haematol. 2002;118:128–131
  30. Goldman J, Liesveld J, Nichols D, et al. ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. Leuk Res. 2003;27:489–491
  31. Bacigalupo A, Van Lint MT, Occhini D, et al. ABO-compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation. 1988;45:1901–1904
  32. Stussi G, Muntwyler J, Passweg JR, et al. Consequences of ABO-incompatibility in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30:87–93
  33. Matsui T, Shimoyama T, Matsumoto M, et al. ABO blood group antigens on human plasma von-Willebrand factor after ABO-mismatched bone marrow transplantation. Blood. 1999;94:2895–2900
  34. Yamamoto F, Clausen H, White T, et al. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345:229–233
  35. Yip SP. Sequence variation at the human ABO locus. Ann Hum Genet. 2002;66:1–27
  36. Eiz-Vesper B, Seltsam A, Blasczyk R. ABO-glycosyltransferases as potential source of minor histocompatibility antigens in allogeneic peripheral blood progenitor cell transplantation. Transfusion. 2005;45:960–968

PII: S1083-8791(08)00008-6

doi: 10.1016/j.bbmt.2008.01.003

Biology of Blood and Marrow Transplantation
Volume 14, Issue 4 , Pages 409-417 , April 2008

Article Tools

* Image Usage & Resolution